<DOC>
	<DOC>NCT01781702</DOC>
	<brief_summary>A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. &amp; Celebrex Cap. for Comparative Evaluation of Safety &amp; Efficacy in Rheumatoid Arthritis Patients</brief_summary>
	<brief_title>Phase 3 Study of Pelubiprofen Tab. &amp; Celebrex Cap. in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1. Adult males/Females aged 18~80 years 2. Patient who are taking NSAIDs for the treatment of rheumatoid arthritis 3. Patients who belong to ACR functional class 1, 2, 3 1. Patients who belong to ACR functional class 4 2. Patients who are hypersensitive to clinical trial medicines or excipient 3. Patients who have experience of Cerebrovascular bleeding, bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>